Document:

EX-10.1

EXHIBIT 10.1

COMMON STOCK PURCHASE AGREEMENT

COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) dated as of December 19, 2006,
between ALTUS PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and GENENTECH,
INC. (the “Purchaser”).

WHEREAS, the parties hereto are simultaneously entering into a Collaboration and License
Agreement (the “Collaboration Agreement”); and

WHEREAS, in connection with the transactions contemplated by the Collaboration Agreement, the
Purchaser desires to purchase from the Company, and the Company desires to issue and sell to the
Purchaser, shares of Common Stock, $0.01 par value per share (the “Common Stock”), of the
Company.

NOW, THEREFORE, in consideration of the mutual promises hereinafter set forth and other good
and valuable consideration, the receipt of which is hereby acknowledged, the parties hereby agree
as follows:

	 	1.	 	Purchase and Sale of the Shares.

(a) Subject to the terms and conditions of this Agreement, at the Closing (as defined in
clause (b) below), the Company will issue and sell to the Purchaser, and the Purchaser will
purchase from the Company, 794,575 shares (the “Shares”) of Common Stock of the Company for
an aggregate purchase price of $15,000,000 (the “Purchase Price”). For the sake of
clarification only, the per share price used to calculate such number of Shares is equal to the
average of the reported last sale price of the Common Stock on the Nasdaq Global Market from
November 28, 2006 through December 18, 2006. The number of Shares to be issued to the Purchaser
hereunder shall be adjusted to reflect fully the effect of any reclassification, stock split,
reverse split, stock dividend, reorganization, recapitalization or other like change with respect
to Common Stock of the Company occurring after the date hereof and prior to the Closing.

(b) The closing of the transactions contemplated hereby (the “Closing”) shall take
place at 10:00 a.m., Eastern time, on a date to be specified by the Company and the Purchaser (the
“Closing Date”), which shall be no later than the fifth business day after satisfaction or
waiver of the conditions to the Closing set forth in Section 4 of this Agreement, remotely via the
exchange of documents and signatures, unless another date, place or time is agreed to in writing by
the Purchaser and the Company. The respective obligations of the parties to this Agreement to
effect the transactions contemplated hereby shall be subject to the delivery of the following at
the Closing:

(i) the Company and the Purchaser shall execute and deliver the Registration Rights Agreement
in the form attached hereto as Exhibit A (the “Registration Rights Agreement”);

(ii) US1DOCS 5965865v8

the Company shall deliver to the Purchaser a certificate of its Secretary or Assistant
Secretary attesting as to the resolutions of the Board of Directors of the Company relating to the
sale of the Shares;

(iii) the Company shall deliver to the Purchaser a certificate as to the corporate good
standing of the Company issued by the Secretary of State of the State of Delaware;

(iv) Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Company, shall deliver to the
Purchaser an opinion, dated the Closing Date, in substantially the form attached hereto as
Exhibit B;

(v) the Purchaser shall pay the Purchase Price to the Company by wire transfer of immediately
available funds to an account designated by the Company; and

(vi) the Company shall instruct the transfer agent for the Common Stock to issue and promptly
deliver to the Purchaser a stock certificate representing the Shares.

2. Representations and Warranties of the Company. The Company represents and warrants
to the Purchaser that the statements contained in this Section 2 are true and correct as of the
date hereof.

(a) Organization and Good Standing. The Company is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware. The Company has the
corporate power and authority to enter into and perform its obligations under this Agreement and
the Registration Rights Agreement, to own and operate its properties and assets and to carry on its
business as currently conducted and as presently proposed to be conducted.

(b) Authorization and Binding Nature. The execution, delivery and performance by the
Company of this Agreement and the Registration Rights Agreement and the issuance and delivery of
the Shares has been duly authorized by all requisite corporate action on the part of the Company
and this Agreement and the Registration Rights Agreement constitute valid and legally binding
obligations of the Company, enforceable against the Company in accordance with their respective
terms, except (i) as may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting the enforcement of creditors’ rights
generally and (ii) as may be limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies.

(c) Non-Contravention. The execution, delivery and performance by the Company of this
Agreement and the Registration Rights Agreement will not, with or without the giving of notice or
the passage of time or both, (i) violate or conflict with the provisions of the certificate of
incorporation or bylaws of the Company, (ii) violate or conflict with any judgment, decree, order
or award of any court, governmental body or arbitrator applicable to the Company, or (iii) violate
or conflict with any material agreement to which the Company is a party or by which it is bound.

(d) Governmental Consents. No consent, approval, order or authorization of, or
registration, qualification, designation, declaration or filing with, any federal, state or local
governmental authority is required on the part of the Company in order to enable the Company to
execute, deliver and perform its obligations under this Agreement, or to execute and deliver the
Registration Rights Agreement, except for such qualifications or filings under applicable
securities laws as may be required to be made after the Closing in connection with the transactions
contemplated by this Agreement.

(e) Authorization of Shares. When issued, sold and delivered in accordance with the
provisions of this Agreement for the consideration expressed herein, the Shares will be duly
authorized, validly issued, fully paid and nonassessable, and will be free of restrictions on
transfer other than restrictions under this Agreement, the Registration Rights Agreement and
applicable state and federal securities laws.

(f) SEC Reports. The Company has previously furnished or made available to the
Purchaser (i) its Annual Report on Form 10-K for the fiscal year ended December 31, 2005, as
amended, as filed with the Securities and Exchange Commission (the “SEC”), and (ii) all
other reports filed by the Company with the SEC under Section 13 or subsections (a) and (c) of
Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) since
January 1, 2006 (such reports are collectively referred to herein as the “Reports”). The
Reports constitute all of the documents required to be filed by the Company under Section 13 or
subsections (a) and (c) of Section 14 of the Exchange Act with the SEC from January 1, 2006 through
the date of this Agreement. The Reports complied in all material respects with the requirements of
the Exchange Act and the rules and regulations thereunder when filed. The Reports, when considered
together, do not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading.

3. Representations and Warranties of the Purchaser. The Purchaser represents and
warrants to the Company that the statements contained in this Section 3 are true and correct as of
the date hereof.

(a) Corporate Power. The Purchaser has the corporate power and authority to enter
into and perform its obligations under this Agreement and the Registration Rights Agreement. The
Purchaser has not been organized, reorganized or recapitalized for the purpose of investing in the
Company.

(b) Authorization and Binding Nature. The execution, delivery and performance by the
Purchaser of this Agreement and the Registration Rights Agreement have been duly authorized by all
requisite corporate action on the part of the Purchaser and this Agreement and the Registration
Rights Agreement constitute valid and legally binding obligations of the Purchaser, enforceable
against the Purchaser in accordance with their respective terms, except (i) as may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting the enforcement of creditors’ rights generally and (ii) as may be limited by laws
relating to the availability of specific performance, injunctive relief or other equitable
remedies.

(c) Non-Contravention. The execution, delivery and performance by the Purchaser of
this Agreement will not, with or without the giving of notice or the passage of time or both, (i)
violate the provisions of the certificate of incorporation or bylaws of the Purchaser, (ii) violate
any judgment, decree, order or award of any court, governmental body or arbitrator applicable to
the Purchaser, or (iii) conflict with or violate any material agreement to which the Purchaser is a
party or by which it is bound.

(d) Accredited Investor. The Purchaser is an “accredited investor,” as defined in
Rule 501 under the Securities Act.

(e) Investment. The Purchaser is acquiring the Shares for its own account for
investment, not for resale to any other person and not with a view to or in connection with any
resale or distribution. The Purchaser understands that the Shares have not been registered under
the securities laws of the United States or any other jurisdiction and cannot be transferred or
resold except as permitted pursuant to a valid registration statement or an applicable exemption
from registration. The Purchaser acknowledges that the Company has not made any representations
with respect to registration of the Shares under applicable securities laws, that there can be no
assurance that any market for the Common Stock will continue into the foreseeable future and that,
as a result, the Purchaser must be prepared to bear the economic risk of its investment for an
indefinite period of time.

(f) Access to Information. The Purchaser has substantial knowledge and experience in
making investment decisions of this type and is capable of evaluating the merits and risks of its
investment in the Company. The Company has made available to the Purchaser all documents and other
information necessary for the Purchaser to evaluate the merits and risks of its investment in the
Company. The Company has made available to the Purchaser all documents requested and has provided
answers to all of its questions relating to an investment in the Company. In evaluating the
suitability of an investment in the Company, the Purchaser has not relied upon any representations
(whether oral or written) other than as set forth herein. The Purchaser has had an opportunity to
discuss this investment with representatives of the Company and to ask questions of them. The
Purchaser understands that an investment in the Company involves significant risks.

4. Conditions to Closing.

(a) Conditions to Obligations of the Purchaser. The Purchaser shall have no
obligation to effect the transactions contemplated hereby until the Effective Date (as such term is
defined in the Collaboration Agreement), at which time the obligations of the Purchaser to effect
the transactions contemplated hereby shall be subject to the delivery by the Company at the Closing
of the items identified in Section 1(b) of this Agreement and the satisfaction on or prior to the
Closing Date of each of the following additional conditions, any of which may be waived, in
writing, exclusively by the Purchaser:

(i) The representations and warranties of the Company set forth in this Agreement shall be
true and correct as of the Closing Date as though made on and as of the Closing Date (except (A) to
the extent such representations and warranties are specifically made as of a particular date, in
which case such representations and warranties shall be true and correct as of such date and
(B) where the failure to be true and correct, individually or in the aggregate, has not had a
Material Adverse Effect); and the Purchaser shall have received a certificate signed on behalf of
the Company by the chief executive officer or the chief financial officer of the Company to such
effect. For purposes of this Agreement, the term “Material Adverse Effect” means a
material adverse change in the business, financial condition or results of operations of the
Company and its subsidiaries, taken as a whole; provided, however, that none of the following shall
constitute, or shall be considered in determining whether there has occurred, a Material Adverse
Effect: (1) changes that are the result of economic factors affecting the national, regional or
world economy or acts of war or terrorism; (2) changes that are the result of factors generally
affecting the industries or markets in which the Company operates; (3) any adverse change arising
out of or resulting from actions contemplated by the parties in connection with this Agreement or
the Collaboration Agreement or the pendency or announcement of the transactions contemplated by
this Agreement or the Collaboration Agreement, including without limitation actions of
collaborators, competitors or employees; (4) changes in law, rules or regulations or generally
accepted accounting principles or the interpretation thereof; (5) any action taken pursuant to or
in accordance with this Agreement or the Collaboration Agreement or at the request of the
Purchaser; (6) any failure by the Company to meet any published securities analyst estimates of
revenues, earnings, expenses or amount of cash for any period ending on or after the date of this
Agreement and prior to the Closing; (7) any loss of collaborators or other business relationships
resulting directly or indirectly from the announcement of the transactions contemplated by this
Agreement or the Collaboration Agreement; (8) any stockholder litigation; and (9) a decline in the
price of the Common Stock of the Company.

(ii) The Collaboration Agreement shall not have been terminated prior to the Closing.

(b) Conditions to Obligations of the Company. The Company shall have no obligation to
effect the transactions contemplated hereby until the Effective Date, at which time the obligations
of the Company to effect the transactions contemplated hereby shall be subject to the delivery by
the Purchaser at the Closing of the items identified in Section 1(b) of this Agreement and the
satisfaction on or prior to the Closing Date of each of the following additional conditions, any of
which may be waived, in writing, exclusively by the Company:

(i) The representations and warranties of the Purchaser set forth in this Agreement shall be
true and correct in all material respects as of the Closing Date as though made on and as of the
Closing Date; and the Company shall have received a certificate signed on behalf of the Purchaser
by an officer of the Company to such effect.

(ii) The Collaboration Agreement shall not have been terminated prior to the Closing.

5. Closing Efforts. Each of the Company and the Purchaser shall use reasonable
commercial efforts to consummate the transactions contemplated by this Agreement.

6. Termination. This Agreement may be terminated (i) at any time by mutual written
consent of the Company and the Purchaser, (ii) by either party if the Collaboration Agreement has
been terminated for any reason prior to the Closing or (iii) by either party if the Closing has not
occurred within 30 days after the Effective Date. In the event that this Agreement is terminated,
the respective obligations of the Company and the Purchaser to sell and purchase the Shares and as
otherwise provided in this Agreement shall become void and be of no further force or effect,
provided that any such termination shall not relieve any party from liability for any breach by
such party, prior to the termination of this Agreement, of any covenant or agreement (but not any
representation or warranty) contained in this Agreement or impair the right of any party to obtain
such remedies as may be available to it in law or equity with respect to such a breach by any other
party.

7. Opinions and Legends. The Purchaser agrees that the Shares shall not be sold or
transferred unless: (i) the Shares shall first have been registered under the Securities Act, (ii)
the Shares are sold pursuant to Rule 144 under the Securities Act of 1933, as amended (the
“Securities Act”) and the Company is furnished with an opinion of counsel reasonably
satisfactory to the Company to the effect that such sale or transfer is exempt from the
registration requirements of the Securities Act or (iii) the Company shall first have been
furnished with an opinion of counsel reasonably satisfactory to the Company to the effect that such
sale or transfer is exempt from the registration requirements of the Securities Act. The Purchaser
understands that the certificate representing the Shares shall bear a legend substantially in the
following form:

“The securities represented by this certificate have not been
registered under the Securities Act of 1933, as amended, and may not
be sold, exchanged, transferred, pledged, hypothecated or otherwise
disposed of unless and until such securities are registered under
such Act or an opinion of counsel satisfactory to the issuer is
obtained to the effect that such registration is not required.”

Promptly after a request from the Purchaser, the foregoing legend shall be removed and the Company
shall issue a certificate without such legend to the holder of any Shares upon which it is stamped,
if, unless otherwise required by state securities laws, (i) the Shares are resold under an
effective registration statement under the Securities Act or (ii) the Shares are eligible for
resale pursuant to Rule 144(k) of the Securities Act and the Company is furnished with an opinion
of counsel reasonably satisfactory to the Company to such effect.

8. Miscellaneous.

(a) Notices. Any notices or other communications required or permitted hereunder
shall be sufficiently given if delivered personally or sent by facsimile or with a reputable
express courier, with charges prepaid, to the address set forth below or to such other address of
which the parties may have given notice. Unless otherwise specified herein, such notices or other
communications shall be deemed received one business day after personal delivery or delivery by
facsimile, or three business days after being sent, if sent by reputable express courier.

If to the Company:

Altus Pharmaceuticals Inc.

125 Sidney Street

Cambridge, Massachusetts 02139

Attention: General Counsel

Facsimile No.: (617) 299-2999

with a copy to:

WilmerHale

60 State Street

Boston, Massachusetts 02109

Attention: Peter N. Handrinos, Esq.

Facsimile No.: (617) 526-5000

If to the Purchaser:

Genentech, Inc.

1 DNA Way

South San Francisco, California 94080

Attn: Corporate Secretary

Facsimile No.: (650) 467-9146

(b) Successors and Assigns. No party may assign its rights or obligations
hereunder without the prior written consent of the other party. Subject to the foregoing, this
Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and assigns. Any assignment in contravention of this provision shall be void.

(c) Survival of Warranties. The representations and warranties of the Company and the
Purchaser contained in or made pursuant to this Agreement shall survive the execution and delivery
of this Agreement and the Closing for one year.

(d) Entire Agreement. This Agreement and the Registration Rights Agreement
represent the entire understanding and agreement between the parties hereto with respect to the
subject matter hereof and supersede all prior oral and written and all contemporaneous oral
negotiations, commitments and understandings between such parties. The parties may amend or modify
this Agreement, in such manner as may be agreed upon, only by a written instrument executed by the
parties hereto.

(e) Expenses. Each party shall pay its own expenses in connection with this
Agreement and the transactions contemplated hereby.

(f) Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware, without reference to conflict of laws principles, and the
parties hereby consent to the jurisdiction of the courts of the State of Delaware.

(g) Section Headings. The section headings are for the convenience of the parties
and in no way alter, modify, amend, limit or restrict the contractual obligations of the parties.

(h) Severability. The invalidity or unenforceability of any provision of this
Agreement shall not affect the validity or enforceability of any other provision of this Agreement.

(i) Counterparts. This Agreement may be executed in two or more counterparts, each
of which shall be deemed to be an original, but all of which shall be one and the same document.

[Remainder of Page Intentionally Left Blank]

1

IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of and on
the date first above written.

ALTUS PHARMACEUTICALS INC.

By: /s/ Sheldon Berkle

Name: Sheldon Berkle

Title: President and Chief Executive Officer

GENENTECH, INC.

By: /s/ Arthur D. Levinson

Name: Arthur D. Levinson

Title: Chairman and Chief Executive Officer

2EX-10.2

EXHIBIT 10.2

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) dated as of February 27, 2007 is entered
into by and among ALTUS PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and
GENENTECH, INC., a Delaware corporation (the “Purchaser”).

Recitals

WHEREAS, the Company and the Purchaser have entered into a Common Stock Purchase Agreement of
even date herewith (the “Purchase Agreement”); and

WHEREAS, the Company and the Purchaser desire to provide for certain arrangements with respect
to the registration of shares of capital stock of the Company under the Securities Act (as defined
below);

NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this
Agreement, the parties hereto agree as follows:

1. Certain Definitions.

As used in this Agreement, the following terms shall have the following respective meanings:

“Affiliate” means any person or entity which, directly or indirectly, controls, is
controlled by or is under common control with the Purchaser.

“Commission” means the Securities and Exchange Commission, or any other federal agency
at the time administering the Securities Act.

“Common Stock” means the common stock, $0.01 par value per share, of the Company.

“Company” has the meaning ascribed to it in the introductory paragraph hereto.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor
federal statute, and the rules and regulations of the Commission issued under such Act, as they
each may, from time to time, be in effect.

“Indemnified Party” means a party entitled to indemnification pursuant to Section 2.4.

“Indemnifying Party” means a party obligated to provide indemnification pursuant to
Section 2.4.

US1DOCS 5966725v6

“Prospectus” means the prospectus included in any Registration Statement, as
amended or supplemented by an amendment or prospectus supplement, including post-effective
amendments, and all material incorporated by reference or deemed to be incorporated by reference in
such Prospectus.

“Purchase Agreement” has the meaning ascribed to it in the recitals hereto.

“Purchaser” has the meaning ascribed to it in the introductory paragraph hereto.

“Registrable Shares” means the shares of Common Stock issued to the Purchaser pursuant
to the Purchase Agreement; provided, however, that shares of Common Stock which are Registrable
Shares shall cease to be Registrable Shares (i) upon the sale of such shares, (ii) upon the
transfer of such shares in any manner to a person or entity which is not entitled, pursuant to
Section 3.1, to the rights provided by this Agreement, (iii) at such time as they become eligible
for sale pursuant to Rule 144(k) under the Securities Act or (iv) at such time as they cease to be
outstanding.

“Registration Expenses” means all expenses incurred by the Company in complying with
the provisions of Section 2, including, without limitation, all registration and filing fees,
exchange listing fees, printing expenses and state Blue Sky fees and expenses, but excluding
underwriting discounts, selling commissions and the fees and expenses of counsel to the Purchaser.

“Registration Statement” means a registration statement on Form S-3 (or any successor
form) filed by the Company with the Commission for a public offering and sale of securities of the
Company.

“Securities Act” means the Securities Act of 1933, as amended, or any successor
federal statute, and the rules and regulations of the Commission issued under such Act, as they
each may, from time to time, be in effect.

2. Registration Rights.

2.1 Required Registration.

(a) At any time after the later of (i) April 30, 2007 and (ii) the date on which the Company
becomes eligible to file a Registration Statement on Form S-3 (or any successor form relating to
secondary offerings), the Purchaser may request, in writing, that the Company effect the
registration on Form S-3 (or such successor form) of the Registrable Shares then owned by the
Purchaser. Upon receipt of any such request for registration, the Company shall use its
commercially reasonable efforts to effect the registration on Form S-3 (or any successor form) of
all Registrable Shares which the Company has been requested by the Purchaser to so register.

(b) The Company shall not be required (i) to effect more than three registrations pursuant to
Section 2.1(a) or (ii) to effect a registration pursuant to Section 2.1(a) involving the
distribution of Registrable Shares by means of an underwriting. For purposes of this Section
2.1(b), a Registration Statement shall not be counted until such time as such Registration
Statement has been declared effective by the Commission (unless the Purchaser withdraws its request
for such registration (other than as a result of information concerning the business or financial
condition of the Company which is made known to the Purchaser after the date on which such
registration was requested) and elects not to pay the Registration Expenses therefor pursuant to
Section 2.4).

(c) If at the time of any request to register Registrable Shares by the Purchaser pursuant to
this Section 2.1, the Company is engaged or has plans to engage in a public offering of securities
solely by, and solely on behalf of, the Company or the Company is engaged in any other activity
which, in the good faith determination of the Company’s Board of Directors, would be adversely
affected by the requested registration, then the Company may at its option direct that such request
be delayed for a period not to exceed 60 consecutive days from the date of such request or an
aggregate of 120 days in any one-year period.

(d) The Company shall be entitled to include shares of Common Stock held by others in any
registration pursuant to this Section 2.1.

2.2 Registration Procedures.

(a) If and whenever the Company is required by the provisions of this Agreement to use its
commercially reasonable efforts to effect the registration of any Registrable Shares under the
Securities Act, the Company shall: (i) promptly file with the Commission a Registration Statement
with respect to such Registrable Shares and use its commercially reasonable efforts to cause that
Registration Statement to become effective as soon as practicable; (ii) use its commercially
reasonable efforts to keep the Registration Statement effective for 90 days from the effective date
or such lesser period until all such Registrable Shares are sold; (iii) promptly furnish to the
Purchaser a copy of the Prospectus, including any preliminary Prospectus, in conformity with the
requirements of the Securities Act, and such other documents as the Purchaser may reasonably
request in order to facilitate the public sale or other disposition of the Registrable Shares; and
(iv) use its commercially reasonable efforts to register or qualify the Registrable Shares covered
by the Registration Statement under the securities or Blue Sky laws of such states of the United
States as the Purchaser shall reasonably request; provided, however, that the Company shall not be
required in connection with this paragraph (iv) to qualify as a foreign corporation or to execute a
general consent to service of process in any jurisdiction or to amend its Certificate of
Incorporation or By-laws in a manner that the Board of Directors of the Company determines is
inadvisable.

(b) If the Company has delivered a Prospectus to the Purchaser and, after having done so, the
Prospectus is amended to comply with the requirements of the Securities Act, the Company shall
promptly notify the Purchaser and, if requested, the Purchaser shall immediately cease making
offers of Registrable Shares and return all Prospectuses to the Company. The Company shall
promptly provide the Purchaser with revised Prospectuses and, following receipt of the revised
Prospectuses, the Purchaser shall be free to resume making offers of the Registrable Shares.

(c) In the event that, in the judgment of the Company, it is advisable to suspend use of a
Prospectus included in a Registration Statement due to pending material developments or other
events that have not yet been publicly disclosed and as to which the Company believes public
disclosure would be detrimental to the Company, the Company shall notify the Purchaser to such
effect, and, upon receipt of such notice, the Purchaser shall immediately discontinue any sales of
Registrable Shares pursuant to such Registration Statement until the Purchaser has received a copy
of a supplemented or amended Prospectus or until the Purchase is advised in writing by the Company
that the then current Prospectus may be used and has received a copy of any additional or
supplemental filings that are incorporated or deemed incorporated by reference in such Prospectus.
Notwithstanding anything to the contrary herein, the Company shall not exercise its rights under
this Section 2.2(c) to suspend sales of Registrable Shares for a period in excess of 60 days
consecutively or 120 days in any 365-day period.

2.3 Allocation of Expenses. The Company will pay all Registration Expenses for all
registrations under this Agreement; provided, however, that if a registration under Section 2.1 is
withdrawn at the request of the Purchaser (other than as a result of information concerning the
business or financial condition of the Company which is made known to the Purchaser after the date
on which such registration was requested) and if the Purchaser elects not to have such registration
counted as a registration requested under Section 2.1, the Purchaser shall pay the Registration
Expenses.

2.4 Indemnification and Contribution.

(a) In the event of any registration of any of the Registrable Shares under the Securities Act
pursuant to this Agreement, the Company will indemnify and hold harmless the Purchaser, each
underwriter of Registrable Shares, and each other person, if any, who controls the Purchaser or
such underwriter within the meaning of the Securities Act or the Exchange Act against any losses,
claims, damages or liabilities, joint or several, to which the Purchaser, such underwriter or such
controlling person may become subject under the Securities Act, the Exchange Act, state securities
or Blue Sky laws or otherwise, insofar as such losses, claims, damages or liabilities (or actions
in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue
statement of any material fact contained in any Registration Statement under which such Registrable
Shares were registered under the Securities Act, any preliminary prospectus or final prospectus
contained in the Registration Statement, or any amendment or supplement to such Registration
Statement, or (ii) the omission or alleged omission to state a material fact required to be stated
therein or necessary to make the statements therein not misleading; and the Company will reimburse
the Purchaser for any reasonable legal or other expenses reasonably incurred by the Purchaser in
investigating or defending any such loss, claim, damage, liability or action; provided, however,
that the Company will not be liable in any such case to the extent that any such loss, claim,
damage or liability arises out of or is based upon any untrue statement or omission made in such
Registration Statement, preliminary prospectus or prospectus, or any such amendment or supplement,
in reliance upon and in conformity with information furnished to the Company, in writing, by or on
behalf of the Purchaser, such underwriter or such controlling person specifically for use in the
preparation thereof or any statement or omission in any prospectus that is corrected in any
subsequent prospectus that was delivered to the Purchaser prior to the pertinent sale or sales by
the Purchaser.

(b) In the event of any registration of any of the Registrable Shares under the Securities Act
pursuant to this Agreement, the Purchaser will indemnify and hold harmless the Company, each of its
directors and officers and each underwriter (if any) and each person (if any) who controls the
Company or any such underwriter within the meaning of the Securities Act or the Exchange Act,
against any losses, claims, damages or liabilities, joint or several, to which the Company, such
directors and officers, underwriter or controlling person may become subject under the Securities
Act, Exchange Act, state securities or Blue Sky laws or otherwise, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any
untrue statement or alleged untrue statement of a material fact contained in any Registration
Statement under which such Registrable Shares were registered under the Securities Act, any
preliminary prospectus or final prospectus contained in the Registration Statement, or any
amendment or supplement to the Registration Statement, or (ii) any omission or alleged omission to
state a material fact required to be stated therein or necessary to make the statements therein not
misleading, if the statement or omission was made in reliance upon and in conformity with
information relating to the Purchaser furnished in writing to the Company by or on behalf of the
Purchaser specifically for use in connection with the preparation of such Registration Statement,
prospectus, amendment or supplement; and the Purchaser will reimburse the Company for any
reasonable legal or other expenses reasonably incurred by the Company in investigating or defending
any such loss, claim, damage, liability or action; provided, however, that the obligations of the
Purchaser hereunder shall be limited to an amount equal to the net proceeds to the Purchaser of
Registrable Shares sold in connection with such registration.

(c) Each Indemnified Party shall give notice to the Indemnifying Party promptly after such
Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall
permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting
therefrom; provided, that counsel for the Indemnifying Party, who shall conduct the defense of such
claim or litigation, shall be approved by the Indemnified Party (whose approval shall not be
unreasonably withheld, conditioned or delayed); and, provided, further, that the failure of any
Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its
obligations under this Section 2.4 except to the extent that the Indemnifying Party is adversely
affected by such failure. The Indemnified Party may participate in such defense at such party’s
expense; provided, however, that the Indemnifying Party shall pay such expense if the Indemnified
Party reasonably concludes that representation of such Indemnified Party by the counsel retained by
the Indemnifying Party would be inappropriate due to actual or potential differing interests
between the Indemnified Party and any other party represented by such counsel in such proceeding;
provided, further that in no event shall the Indemnifying Party be required to pay the expenses of
more than one law firm as counsel for the Indemnified Party. The Indemnifying Party also shall be
responsible for the expenses of such defense if the Indemnifying Party does not elect to assume
such defense. No Indemnifying Party, in the defense of any such claim or litigation shall, except
with the consent of each Indemnified Party, consent to entry of any judgment or enter into any
settlement which does not include as an unconditional term thereof the giving by the claimant or
plaintiff to such Indemnified Party of a release from all liability in respect of such claim or
litigation, and no Indemnified Party shall consent to entry of any judgment or settle such claim or
litigation without the prior written consent of the Indemnifying Party, which consent shall not be
unreasonably withheld, conditioned or delayed.

(d) In order to provide for just and equitable contribution in circumstances in which the
indemnification provided for in this Section 2.4 is due in accordance with its terms but for any
reason is held to be unavailable to an Indemnified Party in respect to any losses, claims, damages
and liabilities referred to herein, then the Indemnifying Party shall, in lieu of indemnifying such
Indemnified Party, contribute to the amount paid or payable by such Indemnified Party as a result
of such losses, claims, damages or liabilities to which such party may be subject in such
proportion as is appropriate to reflect the relative fault of the Company on the one hand and the
Purchaser on the other in connection with the statements or omissions which resulted in such
losses, claims, damages or liabilities, as well as any other relevant equitable considerations.
The relative fault of the Company and the Purchaser shall be determined by reference to, among
other things, whether the untrue or alleged untrue statement of material fact related to
information supplied by the Company or the Purchaser and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission. The
Company and the Purchaser agree that it would not be just and equitable if contribution pursuant to
this Section 2.4(d) were determined by pro rata allocation or by any other method of allocation
which does not take account of the equitable considerations referred to above. Notwithstanding the
provisions of this Section 2.4(d), in no case shall the Purchaser be liable or responsible for any
amount in excess of the net proceeds received by the Purchaser from the offering of Registrable
Shares; provided, however, that no person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person
who was not guilty of such fraudulent misrepresentation. Any party entitled to contribution will,
promptly after receipt of notice of commencement of any action, suit or proceeding against such
party in respect of which a claim for contribution may be made against another party or parties
under this Section 2.4(d), notify such party or parties from whom contribution may be sought, but
the omission to notify such party or parties from whom contribution may be sought shall not relieve
such party from any other obligation it or they may have thereunder or otherwise under this Section
2.4(d). No party shall be liable for contribution with respect to any action, suit, proceeding or
claim settled without its prior written consent, which consent shall not be unreasonably withheld,
conditioned or delayed.

(e) The rights and obligations of the Company and the Purchaser under this Section 2.4 shall
survive the termination of this Agreement.

2.5 Information by Holder. The Company shall not be required to include any
Registrable Shares in any Registration statement unless the Purchaser furnishes the Company in
writing such information regarding the Purchaser and the distribution proposed by the Purchaser as
the Company may reasonably request in writing in connection with a Registration Statement or as
shall be required in connection with any such registration, qualification or compliance. The
Purchaser agrees to report promptly (and in any event within 10 days) all sales or other transfers
of Registrable Shares.

2.6 “Lock-Up” Agreement; Confidentiality of Notices. The Purchaser agrees not to
offer for sale, sell, contract to sell or otherwise dispose of any shares of Common Stock or any
securities that represent the right to receive shares of Common Stock during the 20 days prior to
and the 90 days beginning on the effective date of any underwritten offering of the Company’s
equity securities solely by, and solely on behalf of, the Company unless the Company and the
underwriters managing the offering otherwise agree. The Company and the Purchaser agree that the
provisions of this Section 2.6 shall be enforceable by such underwriter(s) against the Purchaser,
it being understood that such underwriter(s) are intended third party beneficiaries hereof and, if
so requested by such underwriter(s), the Purchaser agrees to execute and deliver to such
underwriter(s) such agreements and instruments, in form and substance reasonably satisfactory to
such underwriter(s) and the Purchaser, further evidencing the Purchaser’s agreement not to sell
such securities during such period. The Company may impose stop-transfer instructions with respect
to the Registrable Shares or other securities subject to the foregoing restriction until the end of
such restricted period. Any written notice from the Company regarding the Company’s plans to file
a Registration Statement and other information related thereto shall be treated by the Purchaser as
confidential and the Purchaser shall not disclose such information to any person.

2.7 Termination. This Agreement shall terminate upon the earlier of (a) two years
after the date hereof and (b) the date on which the Purchaser does not hold any Registrable Shares.

3. General.

3.1 Transfer of Rights. This Agreement, and the rights and obligations of the
Purchaser hereunder, may be assigned by the Purchaser only to an Affiliate to which all of the
Registrable Shares are transferred pursuant to the terms of this Agreement, and, in such case, such
transferee shall be deemed the “Purchaser” for purposes of this Agreement; provided, however, that
such assignment of rights shall be contingent upon the transferee providing a written instrument to
the Company notifying the Company of such transfer and assignment and agreeing in writing to be
bound by the terms of this Agreement.

3.2 Severability. The invalidity or unenforceability of any provision of this
Agreement shall not affect the validity or enforceability of any other provision of this Agreement.

3.3 Specific Performance. In addition to any and all other remedies that may be
available at law in the event of any breach of this Agreement, the parties hereto shall be entitled
to specific performance of the agreements and obligations of the parties hereunder and to such
other injunctive or other equitable relief as may be granted by a court of competent jurisdiction.

3.4 Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware, without reference to conflict of laws principles, and the
parties hereby consent to the jurisdiction of the courts of the State of Delaware.

3.5 Notices. All notices, requests, consents and other communications under this
Agreement shall be in writing and shall be deemed delivered (i) three business days after being
sent by registered or certified mail, return receipt requested, postage prepaid or (ii) one
business day after being sent via a reputable nationwide overnight courier service guaranteeing
next business day delivery, in each case to the intended recipient as set forth below:

If to the Company, at 125 Sidney Street, Cambridge, Massachusetts 02139, Attention: General
Counsel, or at such other address as may have been furnished in writing by the Company to the
Purchaser, with a copy to WilmerHale, 60 State Street, Boston, Massachusetts 02109, Attention:
Peter N. Handrinos, Esq.; or

If to the Purchaser, at 1 DNA Way, South San Francisco, California 94080, Attention: Corporate
Secretary, or at such other address as may have been furnished in writing by the Purchaser to the
Company.

Any party may give any notice, request, consent or other communication under this Agreement
using any other means (including, without limitation, personal delivery, messenger service,
telecopy, first class mail or electronic mail), but no such notice, request, consent or other
communication shall be deemed to have been duly given unless and until it is actually received by
the party for whom it is intended. Any party may change the address to which notices, requests,
consents or other communications hereunder are to be delivered by giving the other parties notice
in the manner set forth in this Section 3.5.

3.6 Complete Agreement. This Agreement constitutes the entire agreement and
understanding of the parties hereto with respect to the subject matter hereof and supersedes all
prior agreements and understandings relating to such subject matter.

3.7 Amendments and Waivers. This Agreement may be amended or terminated and the
observance of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively) with the written consent of the Company and the
Purchaser.

3.8 Counterparts; Facsimile Signatures. This Agreement may be executed in any number
of counterparts, each of which shall be deemed to be an original, and all of which together shall
constitute one and the same document. This Agreement may be executed by facsimile signatures.

3.9 Section Headings and References. The section headings are for the convenience of
the parties and in no way alter, modify, amend, limit or restrict the contractual obligations of
the parties. Any reference in this Agreement to a particular section or subsection shall refer to
a section or subsection of this Agreement, unless specified otherwise.

[Remainder of Page Intentionally Left Blank]

1

IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of and on
the date first above written.

ALTUS PHARMACEUTICALS INC.

By: /s/ Jonathan I. Lieber

Name: Jonathan I. Lieber

Title: Vice President, Chief Financial Officer

and Treasurer

GENENTECH, INC.

By: /s/ David A. Ebersman

Name: David A. Ebersman

Title: Executive Vice President and Chief

Financial Officer

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00118-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00118-of-00352.parquet"}]]